T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...
Bispecific T-cell engagers (TCEs) aim to combat cancer by simultaneously binding T cells and tumor cells in order to induce the first to kill the second. This approach has failed to work effectively ...
In a preclinical study, UC Davis Comprehensive Cancer Center scientists have developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, ...
Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) were recently awarded a $1.8 million, 3-year grant from the United States Department of Defense ...
News-Medical.Net on MSN
New nanomaterial kills cancer cells via oxidative stress
Scientists at Oregon State University have developed a new nanomaterial that triggers a pair of chemical reactions inside cancer cells, killing the cells via oxidative stress while leaving healthy ...
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1’s consistent impact on cancer cell survival pathways. MIAMI, ...
Scientists at Oregon State University have developed a new nanomaterial that triggers a pair of chemical reactions inside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results